Lung Cancer Immunotherapy Featured in CEOCFO Magazine

Batu Biologics’ Lung Cancer Immunotherapy Featured in CEOCFO Magazine
Anti-Angiogenesis Lung Cancer Vaccine Discussed as Potential “Next Generation” Non-Toxic Therapy

Given that the majority of lung cancers are diagnosed late in progression, the majority of patients have limited treatment options, which often carry a heavy burden of toxicity.

Read the full article at businesswire.com

Appoints Biotechnology Industry Veteran

Batu Biologics Appoints Biotechnology Industry Veteran, Dr. Alan Lewis, to Scientific Advisory Board
Former CEO of Medistem to Assist in the FDA Development of the First Anti-Angiogenic Cancer Vaccine for Lung Cancer

The Batu Biologics Team is extremely excited to have Dr. Alan Lewis on board to assist with the development and commercialization of ValloVax™.

Read the full article at businesswire.com